V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Xencor Executive Compensation (FY25)

XNCR · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 18, 2026
247 figures on this page: 237 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
The disclosed peer group names Agenus, Inc., Alector, Inc., Allogene Therapeutics, Inc., Arcus Biosciences, Inc. and Arvinas, Inc., among others. Separately, total compensation for Bassil Dahiyat, President, Chief Executive Officer and Director, came to $5,521,205 in fiscal 2025, and compared with the $6,811,829 reported for fiscal 2024, Dahiyat's total was 18.9% lower, while shareholders recorded 96.6% support for the say-on-pay proposal at the meeting held June 16, 2026 for fiscal 2025. For fiscal 2025, the company reported 5 named executive officers.
Chief executive, fiscal 2025
◇
Bassil Dahiyat
Latest say-on-pay support
=
June 16, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Bassil Dahiyat: $6,811,829 → $5,521,205 (18.9% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Xencor's chief executive and what were they paid?
Total compensation for Bassil Dahiyat, President, Chief Executive Officer and Director, came to $5,521,205 in fiscal 2025. Compared with the $6,811,829 reported for fiscal 2024, Dahiyat's total was 18.9% lower.
What was Xencor's say-on-pay result?
Shareholders recorded 96.6% support for the say-on-pay proposal at the meeting held June 16, 2026 for fiscal 2025.
Which companies are in Xencor's peer group?
The disclosed peer group names Agenus, Inc., Alector, Inc., Allogene Therapeutics, Inc., Arcus Biosciences, Inc. and Arvinas, Inc., among others.
What is Xencor's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 22:1, against median employee compensation of $251,539.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bassil Dahiyat
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
John Desjarlais
Chief Scientific Officer
◇—◇◇◇—◇◇
Celia Eckert
General Counsel
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bassil Dahiyat
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Bart Jan Cornelissen
Chief Financial Officer
◇—◇◇◇—◇◇
Nancy Valente
Former Chief Development Officer
◇—◇◇◇—◇◇
John Desjarlais
Chief Scientific Officer
◇—◇◇◇—◇◇
Celia Eckert
General Counsel
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bassil Dahiyat
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
John Desjarlais
Executive Vice President, Research and Chief Scientific Officer
◇—◇◇◇—◇◇
Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Celia Eckert
Senior Vice President, General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
Nancy Valente
Former Executive Vice President and Chief Development Officer
Departed during or after this year
◇—————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bart Jan CornelissenOPTION◇——◇—◇◇
Bart Jan CornelissenRSU◇——◇——◇
Bassil I. Dahiyat, Ph.D.OPTION◇——◇—◇◇
Bassil I. Dahiyat, Ph.D.RSU◇——◇——◇
Celia E. EckertRSU◇——◇——◇
Celia E. EckertOPTION◇——◇—◇◇
John R. Desjarlais, Ph.D.OPTION◇——◇—◇◇
John R. Desjarlais, Ph.D.RSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
John DesjarlaisRSU◇◇——
Option◇—◇3/2/2033
Option◇—◇3/3/2032
Option◇—◇3/5/2034
RSU◇◇——
RSU◇◇——
Option◇—◇3/4/2035
Bassil DahiyatRSU◇◇——
RSU◇◇——
Option◇—◇3/3/2032
Option◇—◇3/5/2034
RSU◇◇——
Option◇—◇3/4/2035
Option◇—◇3/2/2033
Nancy ValenteRSU◇◇——
Option◇—◇3/5/2034
RSU◇◇——
Option◇—◇5/1/2033
Celia EckertRSU◇◇——
Option◇—◇3/4/2035
RSU◇◇——
Option◇—◇3/5/2034
Option◇—◇3/3/2032
RSU◇◇——
Option◇—◇3/2/2033
Bart CornelissenOption◇—◇3/4/2035
RSU◇◇——
RSU◇◇——
Option◇—◇4/9/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Todd E. Simpson
◇◇◇———◇
Raymond J. Deshaies
◇—◇———◇
A. Bruce Montgomery
◇◇◇———◇
Richard J. Ranieri
◇◇◇———◇
Ellen G. Feigal
◇◇◇———◇
Kurt A. Gustafson
◇◇◇———◇
Barbara Klencke
◇◇◇———◇
Kevin C. Gorman
◇◇◇———◇
Dagmar Rosa-Bjorkeson
◇—————◇
Bassil I. Dahiyat served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agenus, Inc. AGEN
  • Alector, Inc. ALEC
  • Allogene Therapeutics, Inc. ALLO
  • Arcus Biosciences, Inc. RCUS
  • Arvinas, Inc. ARVN
  • Denali Therapeutics Inc. DNLI
  • IDEAYA Biosciences, Inc. IDYA
  • IGM Biosciences, Inc. IGMS
  • Inhibrx, Inc. INBX
  • Iovance Biotherapeutics, Inc. IOVA
  • Kura Oncology, Inc. KURA
  • Relay Therapeutics, Inc. RLAY
  • SpringWorks Therapeutics, Inc. SWTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 16, 2026=◇◇◇
2024June 12, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 14, 2023=◇◇◇
2021June 23, 2022=◇◇◇
2020June 24, 2021=◇◇◇
2019June 25, 2020=◇◇◇
2018June 26, 2019=◇◇◇
2017June 26, 2018=◇◇◇
2016June 22, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Xencor files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Xencor disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Xencor sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Xencor's disclosed peer group is defensible, who names Xencor back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
247 figures on this page: 237 cited to the filing that reported them, 10 calculated from figures it prints.
237 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001326732-26-000045
  2. 0001326732-26-000031
    Director Compensation · EXECUTIVE COMPENSATION COMPENSATION DISCUSSION AND ANALYSIS · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
  3. 0001326732-25-000057
  4. 0001326732-25-000043
    Summary Compensation Table
  5. 0001326732-24-000036
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001326732-24-000017
    Summary Compensation Table
  7. 0001326732-23-000007
  8. 0001558370-22-010382
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001558370-21-008651
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001558370-20-007794
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001558370-19-005963
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001104659-18-042788
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001104659-17-041529
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Xencor executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/XNCR (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Xencor and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Xencor discloses

The companies named in XNCR's own disclosed peer group.

Allogene Therapeutics, Inc.Arcus Biosciences, Inc.Arvinas, Inc.Denali Therapeutics Inc.IDEAYA Biosciences, Inc.Inhibrx, Inc.Kura Oncology, Inc.Relay Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy